QL Biopharm Unveils Oral Once-Weekly GLP-1 Peptide
Beijing-based QL Biopharm plans to progress the oral GLP-1 peptide ZT006 into a Phase II study to evaluate its once-weekly dosing potential in weight management in the fourth quarter.
Scrip - April 27, 2026

Sun Makes Bold Bet With $11.75bn Organon Deal
Sun snaps up Organon in a deal that is set to transform India’s top-ranked drug maker’s standing globally, giving it global scale and a commanding position in areas like women’s health, established brands and biosimilars.
Scrip - April 27, 2026

Quick Listen: Scrip’s Five Must-Know Things
In this week's episode: Iran blockade’s impact on global pharma; Bayer loyal to Europe but wants more; Kailera’s big IPO; 2025’s top drugs; Anthropic taps Novartis’s CEO.
Scrip - April 27, 2026

Edwards Lifesciences Raises Guidance After TAVR Growth Leads Strong Q1
Edwards Lifesciences beat first-quarter expectations in every segment and raised its full-year outlook. The TAVR segment saw 11% growth as major competitors showed weakness – and with the possibility of new Medicare coverage on the horizon, the expansion may continue.
Medtech Insight - April 24, 2026

Nectero’s EAST System Slows AAA Growth In 90% Of Patients Over Two Years
Boston Scientific-backed company’s PGG therapy limited the growth of abdominal aortic aneurysms, with 90% of AAAs growing more slowly than expected; a Phase II/III trial is ongoing.
Medtech Insight - April 24, 2026

MedCon Day 3: Tarver Continues To Hammer Home Use Of Medical Devices
CDRH director Michelle Tarver closed out MedCon 2026 by highlighting the center’s focus on patients and meeting the challenges presented by a rapidly evolving medtech landscape. She also discussed the center’s home health initiative and noted the importance of digital health.
Medtech Insight - April 24, 2026

FreeStyle Libre 3 Recall: 7 Deaths, 860 Injuries, and Now Complaints From India
Abbott's FreeStyle Libre 3 recall – linked with 860 serious injuries, seven deaths, Class I FDA classification – describes sensors reading lower than actual glucose levels. An Indian physician says three of his sensors showed the same issue, while Abbott says Indian sensors meet global standards.
Medtech Insight - April 24, 2026

FDA Issues Early Alert On Medline Syringes
The FDA flagged Medline's angiographic syringes as potentially posing a high risk to patients after a rotating adapter component was found to unwind during use, which could cause biohazard exposure or air embolism.
Medtech Insight - April 24, 2026

EU Unlocks New Funding For Health AI Projects
Seven calls for proposals totaling €63.2m offer a glimpse into the EU’s priorities for AI and digital health.
Medtech Insight - April 24, 2026

Thermo Fisher Raises Guidance As Q1 Results Dodge Tariff Concerns
Company saw Q1 revenues grow by 6%, but shares slid as analysts questioned growth structure.
Medtech Insight - April 24, 2026

US FDA Finds Banned Chemical In Six Gel Nail Polish Removers
FDA testing of gel nail polish removers found six products containing banned ingredient methylene chloride.
HBW Insight - April 25, 2026

Biocon Secures Health Canada Approval For Two Denosumab Biosimilars
Following two more approvals from Health Canada, biosimilars Bosaya and Vevzuo are ready to compete for their market share of denosumab success.
Generics Bulletin - April 24, 2026

Europe Widens Competition Path For Generic Peptides
Europe’s top court has ruled that synthetic medicines may use the EU generic pathway even when the reference product is a biologic, provided Article 10 criteria are met, in a decision with potentially significant implications for peptide competition.
Generics Bulletin - April 24, 2026

EU Nod Arrives For Viatris’s Ibrance Rival
As Viatris received a positive opinion from the EMA’s CHMP for its palbociclib generic, Intas also racked up an endorsement for the region's latest biosimilar rival to Lucentis.
Generics Bulletin - April 24, 2026

Towa Builds Further Backup Network For Drug Shortages
Towa has agreed a manufacturing pact with Sanwa Kagaku Kenkyusho to add backup production capacity, outsource 700 million tablets by FY2028 and strengthen Japan’s off-patent medicines supply through a broader networked manufacturing strategy.
Generics Bulletin - April 24, 2026

Partial Inhibition, Full Ambition: Regeneron Bets Its Neurology Future On Cemdisiran
With an FDA submission confirmed and a priority review voucher in play, Regeneron is targeting a year-end approval, but the competitive math in gMG is unforgiving.
In Vivo - April 22, 2026

Pharma’s Pipeline Size Dipped In 2025
There has been a fall in the number of drugs in development, latest annual data from Citeline show, but the figure is thought to point to a flattening, rather than contracting, of the pipeline.
In Vivo - April 22, 2026

The 10-80-10 Investment Rule: Preparation Is All
It's never an even playing field for healthtech founders seeking investor interest. A high-level BioWales 2026 panel offered advice to hopeful entrepreneurs.
In Vivo - April 22, 2026